All news

NextCure director buys $53,691 of stock after 38% slide

Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash

ADAR1 Capital Management, a 10% owner and director of NextCure (NASDAQ:NXTC), purchased 10,851 shares for $53,691 across three days in late October, at prices from $4.8294 to $5.0953. The buying follows a 38% decline in the stock over six months, even as an InvestingPro Fair Value analysis suggests shares may be overvalued.

Read original source

NXTC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.